Company Overview
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Why Investors Should Care
Return on capital employed stands at 20.5%.
Net profit has compounded at 29.9% per year over the last five years.
Revenue has grown at a 183.6% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $234.60M (+157.0% YoY); net profit $-13.23M.
- Trailing 12 Months Year-on-year growth — revenue -8.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 183.6%, profit CAGR 29.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 183.58% |
| 1 Year: | -8.00% |
Compounded Profit Growth
| 5 Years: | 29.91% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +247.92% |
| 6 Months: | +109.91% |
| 3 Months: | +36.43% |
| 1 Month: | +15.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 20.5%.
- Compounding revenue at 183.6% over 5 years.
- Profit CAGR of 29.9% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANAB AnaptysBio, Inc. R2K | 62.51 | -61.28 | $1.82B | 0.00% | 20.51% | -114.55% | 183.58% | 29.91% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 5.00M | - | 0 | 5.00M | 0 | - | 15.00M | 0 | 0 | 11.25M | 30.03M | 20.89M | 970.00K | 1.22M | 1.29M | 1.37M | 3.46M | 3.32M | 7.18M | 10.97M | 30.02M | - | 27.77M | 22.26M | 76.32M | 108.25M | 25.56M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.31M | 48.43M | 41.62M | 41.35M | 60.19M |
| Operating Income | -1.14M | 2.36M | -1.07M | -3.17M | -9.99M | -2.56M | -9.09M | -7.15M | -15.76M | -14.41M | -16.89M | -19.66M | -24.77M | -26.66M | -33.74M | -22.26M | -10.25M | -22.64M | -24.34M | -18.36M | -533.00K | -6.76M | -31.75M | -27.80M | -29.63M | -44.40M | -40.14M | -37.73M | -42.20M | -40.32M | -22.76M | - | -27.54M | -26.17M | 34.70M | 66.90M | -34.64M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -20.62M | -18.38M | 38.24M | 70.01M | -31.38M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.06M | 19.61M | 22.52M | 19.71M | 20.86M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -39.28M | -38.59M | 15.11M | 49.70M | -52.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.00K | 39.00K | 0 | 81.00K | 40.00K |
| Net Income | -888.00K | 2.32M | -1.11M | - | -11.44M | -2.68M | -9.09M | - | -15.09M | -13.62M | -15.96M | - | -22.08M | -23.96M | -31.03M | - | -8.26M | -21.55M | -23.77M | -18.16M | -429.00K | -6.67M | -36.26M | -32.55M | -33.50M | -44.26M | -39.84M | -37.31M | -43.94M | -46.66M | -32.85M | - | -39.33M | -38.63M | 15.11M | 49.61M | -52.88M |
| Diluted EPS | -0.34 | 0.05 | -0.42 | -1.73 | -0.75 | -0.13 | -0.45 | -0.30 | -0.63 | -0.57 | -0.66 | -0.64 | -0.82 | -0.89 | -1.15 | -0.75 | - | -0.79 | -0.87 | -0.66 | -0.02 | -0.24 | -1.31 | -1.15 | -1.18 | -1.58 | -1.50 | -1.41 | -1.64 | -1.71 | -1.14 | - | -1.28 | -1.34 | 0.52 | 1.58 | -1.84 |
| R&D Expense | 4.79M | 2.33M | 3.28M | - | 7.93M | 7.21M | 6.70M | - | 11.81M | 10.58M | 17.88M | - | 20.63M | 27.35M | 29.93M | - | 20.97M | 17.95M | 19.54M | 24.18M | 25.31M | 22.22M | 22.52M | 20.84M | 22.06M | 34.96M | 32.92M | 30.88M | 37.04M | 42.00M | 42.21M | - | 41.18M | 37.82M | 31.41M | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.57M | 16.68M | 10.00M | 5.00M | 8.00M | 75.00M | 63.17M | 10.29M | 17.16M | 91.28M | 234.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | 125.44M | 174.23M | 206.23M | 186.71M |
| Operating Income | -3.32M | -3.02M | -28.78M | -66.72M | -107.43M | -23.88M | -56.81M | -115.15M | -157.07M | -114.95M | 47.90M |
| EBITDA | - | - | - | - | - | - | - | -105.26M | -143.16M | -92.74M | 69.25M |
| Interest Expense | - | - | - | - | - | - | - | 21.11M | 18.08M | 50.09M | 79.89M |
| Pretax Income | - | - | - | - | - | - | - | -128.70M | -163.62M | -145.23M | -13.07M |
| Tax Provision | - | - | - | - | - | - | - | 24.00K | -4.00K | 3.00K | 164.00K |
| Net Income | -5.41M | -4.26M | -30.07M | -61.66M | -97.34M | -19.93M | -57.80M | -128.72M | -163.62M | -145.23M | -13.23M |
| Diluted EPS | - | -1.62 | -1.52 | -2.50 | -3.60 | -0.73 | -2.11 | -4.57 | -6.08 | -5.12 | -0.46 |
| R&D Expense | 17.30M | 15.42M | 29.44M | 56.20M | 99.34M | 80.03M | 98.50M | 88.80M | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 62.18M | 329.36M | 509.00M | 435.20M | 416.55M | - | 610.38M | 452.39M | 483.83M | 364.39M |
| Current Assets | - | - | - | - | - | - | - | - | 447.20M | 406.83M | 431.88M | 350.25M |
| Cash & Equivalents | - | - | 51.23M | 81.19M | 113.60M | 171.02M | 250.46M | - | 71.31M | 35.97M | 123.08M | 238.20M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | 1.42M | 6.85M | 40.77M | 33.85M |
| Total Liabilities | - | - | - | - | - | - | - | - | 348.28M | 364.29M | 412.97M | 327.19M |
| Current Liabilities | - | - | 5.71M | 14.09M | 21.84M | 29.54M | 19.82M | - | 26.05M | 37.44M | 45.43M | 38.62M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 19.45M | 17.81M | 16.04M | 14.11M |
| Total Equity | -30.84M | -35.18M | -38.25M | 307.58M | 486.37M | 405.01M | 396.73M | - | 262.10M | 88.10M | 70.87M | 37.21M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 28.51M | 26.60M | 30.47M | 28.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.69M | -9.03M | -19.44M | -48.51M | -69.52M | -14.16M | - | -73.59M | -120.80M | -135.34M | 19.70M |
| Investing Cash Flow | -238.00K | -50.00K | -243.06M | -142.45M | 131.43M | 94.47M | - | -394.85M | 144.75M | 95.40M | 228.03M |
| Financing Cash Flow | 39.40M | 8.63M | 292.45M | 223.36M | -4.49M | -879.00K | - | 44.02M | -59.30M | 127.05M | -132.61M |
| Capital Expenditure | -238.00K | -50.00K | -290.00K | -1.06M | -805.00K | -569.00K | - | -358.00K | -807.00K | -358.00K | -87.00K |
| Free Cash Flow | -9.93M | -9.08M | -19.73M | -49.57M | -70.32M | -14.73M | - | -73.95M | -121.61M | -135.69M | 19.61M |
| Net Change in Cash | - | - | - | - | - | - | - | -424.42M | -35.34M | 87.11M | 115.12M |
| Share Buybacks | 0 | 1.00K | 0 | 0 | - | - | 0 | 0 | 50.00M | 456.00K | 68.63M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -18.9% | -18.1% | -287.8% | -1,334.4% | -1,342.9% | -31.8% | -89.9% | -1,119.4% | -915.5% | -125.9% | 20.4% |
| Net Margin % | -30.8% | -25.5% | -300.7% | -1,233.1% | -1,216.7% | -26.6% | -91.5% | -1,251.3% | -953.7% | -159.1% | -5.6% |
| ROE % | 15.4% | 11.1% | -9.8% | -12.7% | -24.0% | -5.0% | - | -49.1% | -185.7% | -204.9% | -35.6% |
| ROCE % | - | -5.4% | -9.1% | -13.7% | -26.5% | -6.0% | - | -19.7% | -37.9% | -26.2% | 14.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 26.61% | 7.88M | $498.73M |
| 2 | Blackrock Inc. | 5.68% | 1.68M | $106.41M |
| 3 | Tang Capital Management, LLC | 4.49% | 1.33M | $84.23M |
| 4 | Morgan Stanley | 3.36% | 993.90K | $62.90M |
| 5 | State Street Corporation | 3.35% | 992.45K | $62.81M |
| 6 | Affinity Asset Advisors, Llc | 3.17% | 940.00K | $59.49M |
| 7 | Vanguard Capital Management LLC | 2.88% | 853.15K | $54.00M |
| 8 | Sanofi | 2.78% | 821.92K | $52.02M |
| 9 | Palo Alto Investors Lp | 2.16% | 638.16K | $40.39M |
| 10 | 683 Capital Management LLC | 2.11% | 625.00K | $39.56M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANAB
What Makes AnaptysBio (ANAB) an Investment Bet?
Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in…
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock w…
How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets
Grupo Traxión is in focus after a major global bank cut its MX$ price target by MX$6, pointing to a more restrained view on the stock. The shift lines up with recent research that adopts a more cautious tone on parts of the story, even as s…
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal fo…
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations businessNow exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with VandaAnnounced appointment of Chris Murphy as …
ANAB — Frequently Asked Questions
What is the current share price of AnaptysBio, Inc. (ANAB)?
As of 2026-07-14 21:23 PDT, AnaptysBio, Inc. (ANAB) trades at $62.51 on NasdaqGS. Its 52-week range is $12.93 to $69.81.
What is the market capitalisation of ANAB?
AnaptysBio, Inc. (ANAB) has a market capitalisation of $1.82B on NasdaqGS.
What is the P/E ratio of ANAB?
ANAB trades at a trailing price-to-earnings (P/E) ratio of -61.28. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 127.72.
What is the return on equity (ROE) of ANAB?
ANAB has a return on equity (ROE) of -114.55%. Its return on capital employed (ROCE) is 20.51%.
Is ANAB a good stock to buy?
This page provides a data-driven analysis of AnaptysBio, Inc. (ANAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.